FIELD: organic chemistry of natural compounds, medicine, pharmacy.
SUBSTANCE: invention elates to a novel polymorphous form © of crystalline irinotecan hydrochloride of the formula: 
This form is characterized by X-ray diffraction picture on a powder with values of angle 2θ about 9.15; about 10.00; about 11.80; about 12.20; about 13.00 and about 13.40 and showing infrared spectrum comprising peaks at 1757, 1712 and 1667 cm-1. The novel polymorphous form © is used in treatment of cancer diseases but as distinct from the known polymorphous form (b) it possesses significantly greater solubility in water that allows its using both oral and parenteral administration.
EFFECT: improved and valuable properties of drug.
19 cl, 2 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYMORPHIC FORMS OF ICOTINIB AND USES THEREOF | 2014 |
|
RU2710013C2 |
| POLYMORPHOUS FORMS OF ICOTINIB MALEATE AND USES THEREOF | 2014 |
|
RU2708079C2 |
| NOVEL POLYMORPHIC FORMS OF ICOTINIB PHOSPHATE AND USES THEREOF | 2014 |
|
RU2712169C2 |
| CRYSTALLINE SOLVATES OF HYDROCHLORIDE 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE | 2012 |
|
RU2619129C2 |
| SALT FORM OF HUMAN HISTONE METHYLTRANSERASE EZH2 INHIBITOR | 2013 |
|
RU2658911C2 |
| METHODS OF PRODUCTION ISOQUINOLINONES AND SOLID FORMS ISOQUINOLINONES | 2012 |
|
RU2626883C2 |
| SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USE | 2012 |
|
RU2611007C2 |
| C-MET/HGFR INHIBITOR POLYMORPHS | 2006 |
|
RU2387650C2 |
| POLYMORPHOUS AND AMORPHOUS FORMS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINE[5,4,3-CD]INDOL-6-ON PHOSPHATE | 2005 |
|
RU2355691C2 |
| SOLID FORMS | 2007 |
|
RU2496780C2 |
